These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 27150701

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T, Lin M, Li W, Fan X, Du T, Zhao Y, Zhang X.
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial.
    Bilz S, Flückiger M, Meienberg F, Falconnier C, Keller U, Puder JJ.
    PLoS One; 2018 Feb; 13(8):e0202007. PubMed ID: 30114246
    [Abstract] [Full Text] [Related]

  • 6. Detemir vs Glargine: Comparison of Inpatient Glycemic Control.
    Capson J, Cade K, Avanesyan A.
    J Am Osteopath Assoc; 2019 Feb 01; 119(2):89-95. PubMed ID: 30688354
    [Abstract] [Full Text] [Related]

  • 7. COMPARISON OF EFFICACY AND SAFETY OF GLARGINE AND DETEMIR INSULIN IN THE MANAGEMENT OF INPATIENT HYPERGLYCEMIA AND DIABETES.
    Galindo RJ, Davis GM, Fayfman M, Reyes-Umpierrez D, Alfa D, Peng L, Tamler R, Pasquel FJ, Umpierrez GE.
    Endocr Pract; 2017 Sep 01; 23(9):1059-1066. PubMed ID: 28683239
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Body Composition and Epicardial Fat in Type 2 Diabetes Patients Following Insulin Detemir Versus Insulin Glargine Initiation.
    Elisha B, Azar M, Taleb N, Bernard S, Iacobellis G, Rabasa-Lhoret R.
    Horm Metab Res; 2016 Jan 01; 48(1):42-7. PubMed ID: 26340704
    [Abstract] [Full Text] [Related]

  • 10. Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: a Randomized, Open-label, Two-period, Cross-over Trial.
    Cherubini V, Pintaudi B, Iannilli A, Pambianchi M, Ferrito L, Nicolucci A.
    Exp Clin Endocrinol Diabetes; 2016 May 01; 124(5):276-82. PubMed ID: 27023008
    [Abstract] [Full Text] [Related]

  • 11. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T.
    Diabetes Obes Metab; 2007 May 01; 9(3):290-9. PubMed ID: 17391154
    [Abstract] [Full Text] [Related]

  • 12. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.
    Luzio SD, Dunseath GJ, Atkinson MD, Owens DR.
    Diabetes Metab; 2013 Dec 01; 39(6):537-42. PubMed ID: 24139704
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.
    Gurkan E, Tarkun I, Sahin T, Cetinarslan B, Canturk Z.
    Diabetes Res Clin Pract; 2014 Dec 01; 106(3):567-75. PubMed ID: 25458329
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V, Heise T, Dellweg S, Elbroend B, Minns I, Home PD.
    Diabet Med; 2009 Oct 01; 26(10):1027-32. PubMed ID: 19900235
    [Abstract] [Full Text] [Related]

  • 17. Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study.
    Lin JC, Shau WY, Lai MS.
    Clin Ther; 2014 Sep 01; 36(9):1255-68. PubMed ID: 25082730
    [Abstract] [Full Text] [Related]

  • 18. The comparison of 24-hour urinary sodium, albumin, and protein excretion in chronic kidney disease patients with type 2 diabetes mellitus using insulin detemir or insulin glargine.
    Afsar B.
    Clin Drug Investig; 2013 Oct 01; 33(10):773-8. PubMed ID: 23943142
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
    Rautio A, Boman K, Gerstein HC, Hernestål-Boman J, Lee SF, Olofsson M, Mellbin LG.
    Diab Vasc Dis Res; 2017 Jul 01; 14(4):345-352. PubMed ID: 28403644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.